Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03051035 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of KO-947 in Non-Hematological Malignancies
A Phase 1 study, sponsored by Kura Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT03051035 is a Phase 1 study that was terminated before completion, run by Kura Oncology. The registered enrollment target is 61 participants.
The verdict
NCT03051035, a Phase 1 study, was terminated before completion, sponsored by Kura Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D) will be determined. In addition, two tumor specific extension cohorts may be conducted to further characterize the safety and tolerability of KO-947 and provide preliminary evidence of anti-tumor activity.
Interventions
- DRUG KO-947
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-04-06 |
| Est. Completion | 2020-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03051035
The ClinicalTrials.gov registry entry for NCT03051035 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kura Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KO-947 is the first listed.
NCT03051035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03051035 about?
NCT03051035 is a clinical study titled "First-in-Human Study of KO-947 in Non-Hematological Malignancies". This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D...
What is the current status of trial NCT03051035?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2017-04-06. Estimated completion is 2020-06-02.
What interventions are being tested in trial NCT03051035?
The interventions under investigation include: KO-947 (DRUG).
Who is sponsoring clinical trial NCT03051035?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.